- Updated indication allows the use of RINVOQ ® (upadacitinib) prior to the use of tumor necrosis factor (TNF) blocking agents in patients for whom use of these treatments is clinically inadvisable ...
AbbVie has reached settlements with all generic drugmakers to resolve litigation that challenged their plans to introduce generics of its arthritis drug Rinvoq, per an MSN report. The generic drug ...
NORTH CHICAGO, Ill., Oct. 29, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from two replicate Phase 3 studies evaluating the safety and efficacy of upadacitinib (RINVOQ ...
NORTH CHICAGO, Ill., Aug. 21, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 UP-AA clinical program evaluating ...
AbbVie settled litigation with companies seeking to make generic versions of Rinvoq. Assuming Rinvoq secures pediatric exclusivity, the drug won't face generic competition until 2037 at the earliest.
(RTTNews) - AbbVie's (ABBV) autoimmune drug Rinvoq has successfully met the endpoints in two replicate phase 3 studies in adult and adolescent patients with non-segmental vitiligo. Non-segmental ...
AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results